Patents by Inventor Robert Loberg

Robert Loberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Biomarkers and use of MET inhibitor for treatment of cancer
    Patent number: 10328062
    Abstract: The present invention relates to methods of therapeutic treatment of cancer using selective tyrosine kinase inhibitors and cancer biomarkers, such as MET amplification and high Met expression for patient selection.
    Type: Grant
    Filed: April 3, 2015
    Date of Patent: June 25, 2019
    Assignee: Amgen, Inc.
    Inventors: Sean Caenepeel, Angela Coxon, Zhiqiang Du, Paul Hughes, Robert Loberg, Gataree Ngarmchamnanrith, Beate Sable
  • BIOMARKERS AND USE OF MET INHIBITOR FOR TREATMENT OF CANCER
    Publication number: 20170182016
    Abstract: The present invention relates to methods of therapeutic treatment of cancer using selective tyrosine kinase inhibitors and cancer biomarkers, such as MET amplification and high Met expression for patient selection.
    Type: Application
    Filed: April 3, 2015
    Publication date: June 29, 2017
    Inventors: Sean CAENEPEEL, Angela COXON, Zhiqiang DU, Paul HUGHES, Robert LOBERG, Gift NGARMCHAMNANRITH, Beate SABLE
  • Compositions and methods for detecting and treating cancer
    Publication number: 20070104717
    Abstract: The present invention relates to compositions and methods for cancer diagnostics and treatment, including but not limited to, CD55 and/or CD97 cancer markers. In particular, the present invention provides compositions and methods of using CD55 and/or CD97 in the diagnosis and treatment of prostate cancers.
    Type: Application
    Filed: September 12, 2006
    Publication date: May 10, 2007
    Applicant: Regents of the University of Michigan
    Inventors: Kenneth Pienta, Robert Loberg